Ibezapolstat

Ibezapolstat (ACX-362E) is a first-in-class, orally active DNA polymerase IIIC (pol IIIC) inhibitor, with a Ki of 0.325 μM for the DNA pol IIIC from C. difficile. Ibezapolstat is developed for the research of C. difficile infection (CDI) [1][2].

Product Specifications

CAS Number

[1275582-97-2]

Product Name Alternative

ACX-362E; GLS-362E

UNSPSC

12352005

Target

Bacterial; DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/acx-362e.html

Purity

98.0

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

O=C1NC(NCC2=CC=C(Cl)C(Cl)=C2)=NC3=C1N(CCN4CCOCC4)C=N3

Molecular Formula

C18H20Cl2N6O2

Molecular Weight

423.30

References & Citations

[1]Beverly Murray, et al. In vitro activity of the novel antibacterial agent ibezapolstat (ACX-362E) against Clostridioides difficile. J Antimicrob Chemother. 2020 Aug 1;75 (8) :2149-2155.|[2]Andrea Torti, et al. Clostridium difficile DNA polymerase IIIC: basis for activity of antibacterial compounds. Curr Enzym Inhib. 2011 Oct; 7 (3) : 147-153.|[3]Sofya Dvoskin, et al. A Novel Agent Effective against Clostridium difficile Infection. Antimicrob Agents Chemother. 2012 Mar; 56 (3) : 1624-1626.